CaverStem™ Adult Stem Cell Therapy for Erectile Dysfunction Receives Positive Reception at International Urology Conference
BY PR Newswire
— 1:25 PM ET 05/23/2018
PHOENIX, May 23, 2018 /PRNewswire/ -- Creative Medical Technology Holdings announced today completion of its 3 day exhibition at the American Urology Association (AUA) meeting. The Company's presentations where delivered by Dr. Alexander Gershman, Director of The Institute of Advanced Urology at the Cedars-Sinai Medical Tower; Director of Urologic Laparoscopy in the Division of Urology, Harbor-UCLA Medical Center and members of Creative Medical Technology Holdings, Inc. ( CELZ Loading...)
"I am very impressed by the strong endorsement we have been receiving from colleagues attending the American Urological Association conference. Since beginning to offer the CaverStem™ procedure in December 2017 we have treated multiple patients of which approximately 90% have reported positive improvements. These are all patients for which pharmacological interventions such as Viagra and Cialis do not work," said Dr. Alexander Gershman. "Whenever a new procedure is introduced to the community, it is fundamentally important to obtain the support of our peers, and to share our findings with our peers. We are enthusiastic by the interest in CaverStem™ by the American and International Urology Community."
In the urology community, Dr. Gershman is regarded as an innovator, being one of the first to introduce laparoscopic and robotic assisted surgery to the discipline. He is considered the world expert on numerous urological innovations, especially in the area of minimally invasive surgery.
"Having Dr. Gershman introduce CaverStem™ to his colleagues and discussing his observations and patient experiences as a treating physician is a very strong endorsement of the CaverStem technology," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings ( CELZ Loading...).
"The CaverStem™ team presenting with Dr. Gershman met physicians not only from the United States but from many other countries as well. The international exposure that the AUA Conference gave to CaverStem™ is invaluable and a strong validation of the interest in our technology across the world."
"Now that the AUA conference is over we have immediately began working on vetting the physicians to insure they meet our criteria, negotiating and preparing contracts. Once this is all completed each physician will be scheduled for training on the use of the device and disposables (kits), their CaverStem™ affiliate website will be launched and the CaverStem™ technology will be marketed in each territory," said Don Dickerson, Chief Financial Officer of Creative Medical Technology Holdings, Inc. ( CELZ Loading...)
Creative Medical Health Technology Holdings is offering the CaverStem™ procedure to selected physicians who qualify according to the Company's criteria. Approximately 30% of the 30,000,000 patients in the United States suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the biological machinery needed to achieve erections.
Aloha
BY PR Newswire
— 1:25 PM ET 05/23/2018
PHOENIX, May 23, 2018 /PRNewswire/ -- Creative Medical Technology Holdings announced today completion of its 3 day exhibition at the American Urology Association (AUA) meeting. The Company's presentations where delivered by Dr. Alexander Gershman, Director of The Institute of Advanced Urology at the Cedars-Sinai Medical Tower; Director of Urologic Laparoscopy in the Division of Urology, Harbor-UCLA Medical Center and members of Creative Medical Technology Holdings, Inc. ( CELZ Loading...)
"I am very impressed by the strong endorsement we have been receiving from colleagues attending the American Urological Association conference. Since beginning to offer the CaverStem™ procedure in December 2017 we have treated multiple patients of which approximately 90% have reported positive improvements. These are all patients for which pharmacological interventions such as Viagra and Cialis do not work," said Dr. Alexander Gershman. "Whenever a new procedure is introduced to the community, it is fundamentally important to obtain the support of our peers, and to share our findings with our peers. We are enthusiastic by the interest in CaverStem™ by the American and International Urology Community."
In the urology community, Dr. Gershman is regarded as an innovator, being one of the first to introduce laparoscopic and robotic assisted surgery to the discipline. He is considered the world expert on numerous urological innovations, especially in the area of minimally invasive surgery.
"Having Dr. Gershman introduce CaverStem™ to his colleagues and discussing his observations and patient experiences as a treating physician is a very strong endorsement of the CaverStem technology," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings ( CELZ Loading...).
"The CaverStem™ team presenting with Dr. Gershman met physicians not only from the United States but from many other countries as well. The international exposure that the AUA Conference gave to CaverStem™ is invaluable and a strong validation of the interest in our technology across the world."
"Now that the AUA conference is over we have immediately began working on vetting the physicians to insure they meet our criteria, negotiating and preparing contracts. Once this is all completed each physician will be scheduled for training on the use of the device and disposables (kits), their CaverStem™ affiliate website will be launched and the CaverStem™ technology will be marketed in each territory," said Don Dickerson, Chief Financial Officer of Creative Medical Technology Holdings, Inc. ( CELZ Loading...)
Creative Medical Health Technology Holdings is offering the CaverStem™ procedure to selected physicians who qualify according to the Company's criteria. Approximately 30% of the 30,000,000 patients in the United States suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the biological machinery needed to achieve erections.
Aloha
1
